Aung Naing
M.D. Anderson Cancer Center · UT MD Anderson Cancer Center · MD Anderson Cancer Centre, 1515 Holcombe Blvd, Houston, Texas, USA
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Aung Naing as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 18:17 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07500298 · Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal CancerM.D. Anderson Cancer Center · recruiting · Phase 1, SAR445877, FOlfox6 · principal investigator
- Ph1NCT06990698 · A Phase 1 Study to Investigate FP008 in Subjects With Advanced Solid TumorsZhuhai Fapon Biopharma Co., Ltd. · recruiting · Advanced Solid Tumors · principal investigator
- Ph2NCT06651593 · Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid TumorsM.D. Anderson Cancer Center · recruiting · Solid Tumors · principal investigator
- Ph2NCT06567314 · Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell CarcinomaM.D. Anderson Cancer Center · recruiting · Cutaneous Squamous Cell Carcinoma · principal investigator
- Ph1NCT06563375 · Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid TumorsM.D. Anderson Cancer Center · recruiting · Solid Tumor · principal investigator
- Ph1NCT06163391 · A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic CancerSOTIO Biotech AG · active not recruiting · Advanced Solid Tumor, Metastatic Solid Tumor · principal investigator
- Ph1/Ph2NCT05672459 · A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid TumorsM.D. Anderson Cancer Center · active not recruiting · Solid Tumor · principal investigator
- Ph2NCT04171219 · Talabostat and Pembrolizumab for the Treatment of Advanced Solid CancersM.D. Anderson Cancer Center · terminated · Advanced Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm · principal investigator
- Ph1NCT03852511 · First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)Akamis Bio · completed · Metastatic Cancer, Epithelial Tumor · principal investigator
- Ph1/Ph2NCT03217747 · Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced MalignanciesM.D. Anderson Cancer Center · active not recruiting · Advanced Malignant Solid Neoplasm, Castration-Resistant Prostate Carcinoma, Malignant Solid Neoplasm · principal investigator
- Ph2NCT02721732 · Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are MetastaticM.D. Anderson Cancer Center · active not recruiting · Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary, Metastatic Adrenal Gland Pheochromocytoma · principal investigator
- Ph1NCT02419495 · Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesM.D. Anderson Cancer Center · terminated · Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 · principal investigator
- Ph1NCT02159989 · Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryNational Cancer Institute (NCI) · completed · Advanced Malignant Solid Neoplasm, Fibrolamellar Carcinoma, Metastatic Malignant Solid Neoplasm · principal investigator
- Ph3NCT01952847 · Randomized Trial of Glutamine in Patients With Mucositis or EsophagitisM.D. Anderson Cancer Center · terminated · Advanced Cancers · principal investigator
- Ph1NCT01529593 · Temsirolimus in Combination With Metformin in Patients With Advanced CancersM.D. Anderson Cancer Center · terminated · Advanced Cancers · principal investigator
- N/ANCT01462383 · The Role of the EKG in Anticancer Drug DevelopmentM.D. Anderson Cancer Center · completed · Advanced Cancer · principal investigator
- Ph1NCT01432119 · Phase 1 Trial With SIR-Spheres and Cetuximab +/- ErlotinibM.D. Anderson Cancer Center · withdrawn · Advanced Cancers · principal investigator
- N/ANCT00949390 · Complementary and Alternative Medicine Usage Among Participants Enrolled in Phase I Oncology Clinical TrialsM.D. Anderson Cancer Center · completed · Advanced Cancer · principal investigator
- Ph1NCT00752011 · Phase I Study of TAS-106 in Combo With CarboplatinM.D. Anderson Cancer Center · completed · Cancer, Solid Tumors · principal investigator
- Ph1NCT00731263 · A Study of Tor Kinase Inhibitor in Advanced TumorsAstraZeneca · completed · Solid Tumors · principal investigator
- Ph1NCT00678769 · Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic CancerNational Cancer Institute (NCI) · completed · Malignant Neoplasm · principal investigator
- Ph1NCT00658970 · Evaluation of KX2-391 in Patients With Advanced MalignanciesAthenex, Inc. · completed · Solid Tumors, Lymphoma · principal investigator
- Ph1NCT00629200 · Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced MalignanciesM.D. Anderson Cancer Center · completed · Advanced Cancer, Solid Tumors · principal investigator
- Ph1NCT00495872 · Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid TumorM.D. Anderson Cancer Center · completed · Solid Tumors · principal investigator
- Ph1NCT00489593 · Olanzapine in Patients With Advanced Cancer and Weight LossM.D. Anderson Cancer Center · completed · Advanced Cancer, Weight Loss · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 18:17 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Integrating patient-reported outcomes and T-cell receptor sequencing to predict immune-related adverse eventsR01CA279749 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2024 to 2026 · $635,751 awarded in 2026Same name and institution; not confirmed by an ID
- Phase I Study of IMC-A12 in Combination with TemsirolimusR21CA137633 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2009 to 2010 · $332,334 awarded in 2010Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Experimental Medicine ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2013 to 2026Named on NCT02159989, NCT00678769
- U01CA062461RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT02159989, NCT00678769
- Texas EXperimental Cancer Therapeutics Network - TEX CTNUM1CA186688 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM, John Sarantopoulos, James C Yao · fiscal years 2014 to 2026Named on NCT02159989
- Early Clinical Trials of New Anti-Cancer AgentsU01CA062487 · NCI · WAYNE STATE UNIVERSITY · PI Patricia M. LoRusso · fiscal years 2013Named on NCT00678769
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 18:17 UTC. The ranking covers the 200 most relevant of 158 PubMed records, and a shared surname and initials can bring in a namesake. All 158 on PubMed
- 630 citationsRCR 22.9
- Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.Nat Med · 2023357 citationsRCR 30.6
- Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors.Clin Cancer Res · 2021320 citationsRCR 15.3
- Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.Clin Cancer Res · 2017281 citationsRCR 8.7
- 209 citationsRCR 5.4
- A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas.Clin Cancer Res · 2012207 citationsRCR 5.8
- 201 citationsRCR 4.8
- 192 citationsRCR 5.1
- Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.J Clin Oncol · 2016186 citationsRCR 5.2
- MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study.Lancet Oncol · 2014175 citationsRCR 4.7